See more : C29 Metals Limited (C29.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Calidi Biotherapeutics, Inc. (CLDI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calidi Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SoftBank Group Corp. (9984.T) Income Statement Analysis – Financial Results
- Luminex Corporation (LMNX) Income Statement Analysis – Financial Results
- Knorr-Bremse Aktiengesellschaft (KNBHF) Income Statement Analysis – Financial Results
- CHP Merger Corp. (CHPMW) Income Statement Analysis – Financial Results
- Stack Capital Group Inc. (STCK.TO) Income Statement Analysis – Financial Results
Calidi Biotherapeutics, Inc. (CLDI)
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 45.00K | 449.00K | 0.00 |
| Cost of Revenue | 1.26M | 274.00K | 94.00K | 0.00 |
| Gross Profit | -1.26M | -229.00K | 355.00K | 0.00 |
| Gross Profit Ratio | 0.00% | -508.89% | 79.06% | 0.00% |
| Research & Development | 13.01M | 7.26M | 4.67M | 3.18M |
| General & Administrative | 15.98M | 15.90M | 6.16M | 3.59M |
| Selling & Marketing | 0.00 | -260.00K | -4.38M | 0.00 |
| SG&A | 15.98M | 15.64M | 1.78M | 3.59M |
| Other Expenses | 0.00 | -5.00K | 9.00K | 4.00K |
| Operating Expenses | 28.99M | 22.90M | 1.78M | 6.77M |
| Cost & Expenses | 28.99M | 23.17M | 1.78M | 6.77M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.07M | 158.00K | 614.00K | 163.00K |
| Depreciation & Amortization | 1.26M | 260.00K | 153.00K | 117.00K |
| EBITDA | -27.58M | -25.00M | -9.45M | -6.65M |
| EBITDA Ratio | 0.00% | -50,817.78% | -396.82% | 0.00% |
| Operating Income | -28.99M | -23.13M | -1.78M | -6.77M |
| Operating Income Ratio | 0.00% | -51,395.56% | -396.82% | 0.00% |
| Total Other Income/Expenses | -208.00K | -2.29M | -440.00K | -1.16M |
| Income Before Tax | -29.20M | -25.42M | 3.39M | -7.93M |
| Income Before Tax Ratio | 0.00% | -56,480.00% | 754.29% | 0.00% |
| Income Tax Expense | 16.00K | 11.00K | 11.00K | 4.00K |
| Net Income | -29.22M | -25.43M | 3.39M | -7.94M |
| Net Income Ratio | 0.00% | -56,504.44% | 754.29% | 0.00% |
| EPS | -1.73 | -29.90 | 1.18 | -0.22 |
| EPS Diluted | -17.30 | -29.90 | 1.18 | -0.22 |
| Weighted Avg Shares Out | 16.89M | 850.50K | 2.88M | 35.91M |
| Weighted Avg Shares Out (Dil) | 1.69M | 850.50K | 2.88M | 35.91M |
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Calidi to Effect Reverse Stock Split
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Source: https://incomestatements.info
Category: Stock Reports